|

Epcoritamab Clinical Trials

25 actively recruiting trials across 17 locations

▲ +2 trials since June 2026

Also known as: ABBV-GMAB-3013, ABBV-GMAB-3013;, Anti-CD20/CD3 Bispecific Antibody GEN3013, DuoBody -CD3xCD20, DuoBody-CD3xCD20 +7 more

Pipeline

Phase 1: 3Phase 2: 19Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Reid Merryman, MD2
  • City of Hope Medical Center2
  • Zulfa Omer1
  • Yazeed Sawalha1
  • University of Washington1

Indications

  • Cancer25
  • Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified3
  • Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified3
  • Refractory Diffuse Large B-Cell Lymphoma3
  • Follicular Lymphoma3

Other5 trials

Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Phase 2
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Phase 2
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Phase 2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Phase 2
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
Phase 2

Boston, Massachusetts3 trials

Epco, Zanu, Ritux for R/R FL or MZL

Dana-Farber Cancer Institute

Phase 2
Epcoritamab and Rituximab for First-line Follicular Lymphoma

Beth Israel Deaconess Medical Center

Phase 2
Epcoritamab in Previously Treated WM

Beth Israel Deaconess Medical Center

Phase 2

Duarte, California2 trials

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

City of Hope Medical Center

Phase 2

Phoenix, Arizona1 trial

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Mayo Clinic in Arizona - Phoenix

Phase 1/2

Fresno, California1 trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

UCSF Fresno /ID# 264712

Phase 3

Sacramento, California1 trial

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

University of California Davis Comprehensive Cancer Center

Phase 2

Stanford, California1 trial

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Stanford

Phase 2

Miami, Florida1 trial

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

University of Miami

Phase 2

Chicago, Illinois1 trial

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Northwestern University

Phase 2

Indianapolis, Indiana1 trial

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 2

Minneapolis, Minnesota1 trial

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

University of Minnesota/Masonic Cancer Center

Phase 1/2

Rochester, Minnesota1 trial

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Mayo Clinic in Rochester

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

Cincinnati, Ohio1 trial

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

University of Cincinnati

Phase 2

Cleveland, Ohio1 trial

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Phase 1

Philadelphia, Pennsylvania1 trial

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Abramson Cancer Center at the University of Pennsylvania

Phase 2

Salt Lake City, Utah1 trial

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

Huntsman Cancer Institute at University of Utah

Phase 1

Seattle, Washington1 trial

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.